Scolaris Content Display Scolaris Content Display

داروهای ضدبارداری ترکیبی: تاثیرات بر وزن

Appendices

Appendix 1. Search 2013

MEDLINE via PubMed (01 Jan 2011 to 01 Jan 2014)

("Contraceptive Agents, Female"[Mesh] OR "Contraceptive Devices, Female"[Mesh] OR contracept*[tiab]) AND ("Body Weight"[Mesh] OR weight[tiab] OR "Body Mass Index"[Mesh]) NOT (cancer*[ti] OR polycystic [ti] OR exercise [ti] OR physical activity[ti] OR postmenopaus*[ti])
Filter Activated: Clinical Trial

CENTRAL (01 Jan 2011 to 11 Nov 2013)

contracept* in Title, Abstract, or Keywords
AND (weigh* OR body mass index) in Abstract

POPLINE (01 Jan 2011 to 06 Nov 2013)

All fields: (contraceptive agents OR contraceptive devices) AND weight

Filter by keywords: research report

EMBASE (01 Jan 2011 to 11 Nov 2013)

'weight'/exp OR weight AND contracept* AND ([controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR [conference abstract]/lim OR [conference paper]/lim OR [erratum]/lim) AND ([obstetrics and gynecology]/lim OR [public health]/lim) AND [humans]/lim AND [embase]/lim AND [2011‐2014]/py

LILACS (01 Jan 2011 to 06 Nov 2013)

(contraceptive agents, female or agentes anticonceptivos femeninos or anticoncepcionais femeninos) AND
(weight or weight gain or weight loss or peso or aumento de peso or ganho de peso or peridida de peso or perda de peso)

ClinicalTrials.gov (01 Jan 2011 to 11 Nov 2013)

Intervention: contraceptive OR contraception
Outcomes: weight OR body mass index
Studies with female participants
Study type: interventional

ICTRP (01 Jan 2011 to 07 Nov 2013)

1) contracept* AND weight

2) contracept* AND body mass index

Appendix 2. Previous search

MEDLINE via PubMed (31 May 2011)

("Contraceptive Agents, Female"[Mesh] OR "Contraceptive Devices, Female"[Mesh] OR contracept*[tiab]) AND ("Body Weight"[Mesh] OR weight[tiab] OR "Body Mass Index"[Mesh]) NOT (cancer*[ti] OR polycystic [ti] OR exercise [ti] OR physical activity[ti] OR postmenopaus*[ti])
Limits Activated: Humans, Clinical Trial, Randomized Controlled Trial

POPLINE (24 Jan 2011)

(contraceptive agents / contraceptive devices) & (random* / blind* / placebo* / crossover*) & weight

CENTRAL (22 Feb 2011)

contracept* in Title, Abstract, or Keywords
AND (weigh* OR body mass index) in Abstract

EMBASE (22 Feb 2011)

s weight(w)gain
and
s contracept? OR contraceptive agent?
and
s3 and pd=20080523:20110222
and
s human
and
s clinical trial

LILACS (25 Feb 2011)

(contraceptive agents, female or agentes anticonceptivos femeninos or anticoncepcionais femeninos) AND
(weight or weight gain or weight loss or peso or aumento de peso or ganho de peso or peridida de peso or perda de peso)

ClinicalTrials.gov (24 Jan 2011)

Intervention: contraceptive OR contraception
Outcomes: weight OR body mass index
Studies with female participants
Study type: interventional

ICTRP (09 Feb 2011)

1) contracept* AND weight

2) contracept* AND body mass index

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).
Figuras y tablas -
Analysis 1.1

Comparison 1 Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).

Comparison 2 Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).
Figuras y tablas -
Analysis 2.1

Comparison 2 Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).

Comparison 3 Levonorgestrel 100 µg and EE 20 µg versus placebo, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 3.1

Comparison 3 Levonorgestrel 100 µg and EE 20 µg versus placebo, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 4 Norgestrel 300 µg and EE 30 µg versus no intervention, Outcome 1 Mean weight change in kg per year.
Figuras y tablas -
Analysis 4.1

Comparison 4 Norgestrel 300 µg and EE 30 µg versus no intervention, Outcome 1 Mean weight change in kg per year.

Comparison 5 Norethindrone 1 mg and mestranol 50 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).
Figuras y tablas -
Analysis 5.1

Comparison 5 Norethindrone 1 mg and mestranol 50 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 1 Gained >5% baseline weight (cycle 9).
Figuras y tablas -
Analysis 6.1

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 1 Gained >5% baseline weight (cycle 9).

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 2 Lost >5% baseline weight (cycle 9).
Figuras y tablas -
Analysis 6.2

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 2 Lost >5% baseline weight (cycle 9).

Comparison 7 Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen, Outcome 1 Mean weight change (112 days or cycle 4).
Figuras y tablas -
Analysis 7.1

Comparison 7 Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen, Outcome 1 Mean weight change (112 days or cycle 4).

Comparison 8 Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 8.1

Comparison 8 Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean body mass percentage change (cycle 6).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 9.1

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 9.2

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 3 Gained >2 kg (cycle 12).
Figuras y tablas -
Analysis 9.3

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 3 Gained >2 kg (cycle 12).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 4 Lost >2 kg (cycle 12).
Figuras y tablas -
Analysis 9.4

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 4 Lost >2 kg (cycle 12).

Comparison 10 Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 10.1

Comparison 10 Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean body mass percentage change (cycle 6).

Comparison 11 Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 11.1

Comparison 11 Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 12 Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen, Outcome 1 Gained >2 kg (cycle 7).
Figuras y tablas -
Analysis 12.1

Comparison 12 Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen, Outcome 1 Gained >2 kg (cycle 7).

Comparison 13 Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 13.1

Comparison 13 Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 14.1

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 14.2

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 15.1

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 15.2

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 16.1

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 16.2

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).

Comparison 17 Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 17.1

Comparison 17 Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 18 Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 18.1

Comparison 18 Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 3).
Figuras y tablas -
Analysis 19.1

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 3).

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 3).
Figuras y tablas -
Analysis 19.2

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 3).

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 20.1

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 20.2

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 21.1

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 21.2

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 13).
Figuras y tablas -
Analysis 22.1

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 13).

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 13).
Figuras y tablas -
Analysis 22.2

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 13).

Comparison 23 Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg, Outcome 1 Mean weight change in kg (cycle 7).
Figuras y tablas -
Analysis 23.1

Comparison 23 Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg, Outcome 1 Mean weight change in kg (cycle 7).

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 24.1

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 24.2

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 25 Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 25.1

Comparison 25 Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 26.1

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 26.2

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 3 Gained >2 kg (cycle 12).
Figuras y tablas -
Analysis 26.3

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 3 Gained >2 kg (cycle 12).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 4 Lost >2 kg (cycle 12).
Figuras y tablas -
Analysis 26.4

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 4 Lost >2 kg (cycle 12).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 5 Gained >2 kg (cycle 13).
Figuras y tablas -
Analysis 26.5

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 5 Gained >2 kg (cycle 13).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 6 Lost >2 kg (cycle 13).
Figuras y tablas -
Analysis 26.6

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 6 Lost >2 kg (cycle 13).

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 27.1

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean body mass percentage change (cycle 6).

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 2 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 27.2

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 2 Mean weight change in kg (cycle 6).

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 3 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 27.3

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 3 Mean weight change in kg (cycle 12).

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 28.1

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg ( cycle 6).
Figuras y tablas -
Analysis 28.2

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg ( cycle 6).

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 3 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 28.3

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 3 Mean body mass percentage change (cycle 6).

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 29.1

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 2 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 29.2

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 2 Mean body mass percentage change (cycle 6).

Comparison 30 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 30.1

Comparison 30 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 31 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 31.1

Comparison 31 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 32 Prolonged gestodene and EE regimen versus standard gestodene and EE regimen, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 32.1

Comparison 32 Prolonged gestodene and EE regimen versus standard gestodene and EE regimen, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 33.1

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 33.2

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.5 kg (cycle 24).
Figuras y tablas -
Analysis 34.1

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.5 kg (cycle 24).

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2.5 kg (cycle 24).
Figuras y tablas -
Analysis 34.2

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2.5 kg (cycle 24).

Comparison 35 Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 35.1

Comparison 35 Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 36 Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.7 kg (cycle 6).
Figuras y tablas -
Analysis 36.1

Comparison 36 Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.7 kg (cycle 6).

Comparison 37 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 37.1

Comparison 37 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 1 Mean BMI change (cycle 6).
Figuras y tablas -
Analysis 38.1

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 1 Mean BMI change (cycle 6).

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 2 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 38.2

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 2 Mean weight change in kg (cycle 6).

Comparison 39 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 39.1

Comparison 39 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 40 Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 40.1

Comparison 40 Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 41 Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 41.1

Comparison 41 Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 1 Gained >2.5 kg (cycle 12).
Figuras y tablas -
Analysis 42.1

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 1 Gained >2.5 kg (cycle 12).

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 2 Lost >2.5 kg (cycle 12).
Figuras y tablas -
Analysis 42.2

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 2 Lost >2.5 kg (cycle 12).

Comparison 43 Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 43.1

Comparison 43 Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 44.1

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 44.2

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Mean body mass percentage change (cycle 6).

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 45.1

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 45.2

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 46 Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 46.1

Comparison 46 Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Weight gain >=5% (cycle 6).
Figuras y tablas -
Analysis 47.1

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Weight gain >=5% (cycle 6).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Weight gain >=5% (cycle 13).
Figuras y tablas -
Analysis 47.2

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Weight gain >=5% (cycle 13).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 3 Weight loss >=5% (cycle 6).
Figuras y tablas -
Analysis 47.3

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 3 Weight loss >=5% (cycle 6).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 4 Weight loss >=5% (cycle 13).
Figuras y tablas -
Analysis 47.4

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 4 Weight loss >=5% (cycle 13).

Comparison 48 Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 48.1

Comparison 48 Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 49 Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 49.1

Comparison 49 Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Gain >2 kg (cycle 4).
Figuras y tablas -
Analysis 50.1

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Gain >2 kg (cycle 4).

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 4).
Figuras y tablas -
Analysis 50.2

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 4).

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gain >=7% body weight (cycle 13).
Figuras y tablas -
Analysis 51.1

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gain >=7% body weight (cycle 13).

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >=7% body weight (cycle 13).
Figuras y tablas -
Analysis 51.2

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >=7% body weight (cycle 13).

Comparison 52 Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 13 or last assessment).
Figuras y tablas -
Analysis 52.1

Comparison 52 Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 13 or last assessment).

Table 1. Discontinuation due to weight change

Study ID

Intervention group

n

N (randomized women)

Cachrimanidou 1993

Prolonged desogestrel / ethinyl estradiol (EE) regimen

10

200

Standard desogestrel / EE regimen

1

100

Coenen 1996

Norgestimate 250 μg / EE 35 μg

1

25

Gestodene 75 μg / EE 30 μg

0

25

Desogestrel 150 μg / EE 30 μg

0

25

Desogestrel 150 μg / EE 20 μg

0

25

Coney 2001

Levonorgestrel 100 μg / EE 20 μg

2

359

Placebo

0

362

Dionne 1974

Levonorgestrel 250 μg / EE 50 μg

3

73

Levonorgestrel 150 μg / EE 30 μg

1

77

Halbe 1998

Gestodene 75 μg / EE 30 μg

4

279

Desogestrel 150 μg / EE 30 μg

0

316

Kirkman 1994

Gestodene 75 μg / EE 30 μg

4

505

Desogestrel 150 μg / EE 20 μg

2

501

Miller 2001

Standard norgestrel / EE regimen

0

44

Prolonged norgestrel / EE regimen

1

46

Oddsson 2005

Vaginal ring etonogestrel 120 µg / EE 15 µg

2

512

Levonorgestrel 150 µg / EE 30 µg

6

518

Sang 1995

Injectable medroxyprogesterone acetate 25 mg / estradiol cypionatge (EC) 5 mg

14

1955

Injectable norethisterone enanthate 50 mg / estradiol valerate (EV) 5 mg

10

1960

Wiik 1993

Norethisterone 500‐1000 μg / EE 35 μg

3

100

Levonorgestrel 50‐75‐125 μg / EE 30‐40 μg

1

96

Figuras y tablas -
Table 1. Discontinuation due to weight change
Comparison 1. Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.3 kg (cycle 4) Show forest plot

1

113

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.02 [0.46, 2.26]

Figuras y tablas -
Comparison 1. Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo
Comparison 2. Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.3 kg (cycle 4) Show forest plot

1

112

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.57 [0.24, 1.33]

Figuras y tablas -
Comparison 2. Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo
Comparison 3. Levonorgestrel 100 µg and EE 20 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

473

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐0.23, 0.83]

Figuras y tablas -
Comparison 3. Levonorgestrel 100 µg and EE 20 µg versus placebo
Comparison 4. Norgestrel 300 µg and EE 30 µg versus no intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg per year Show forest plot

1

150

Mean Difference (IV, Fixed, 95% CI)

‐0.54 [‐1.39, 0.31]

Figuras y tablas -
Comparison 4. Norgestrel 300 µg and EE 30 µg versus no intervention
Comparison 5. Norethindrone 1 mg and mestranol 50 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.3 kg (cycle 4) Show forest plot

1

123

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.50 [0.22, 1.17]

Figuras y tablas -
Comparison 5. Norethindrone 1 mg and mestranol 50 µg versus placebo
Comparison 6. Skin patch norelgestromin 150 µg and EE 20 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 9) Show forest plot

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.30, 2.98]

2 Lost >5% baseline weight (cycle 9) Show forest plot

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.27 [0.04, 1.82]

Figuras y tablas -
Comparison 6. Skin patch norelgestromin 150 µg and EE 20 µg versus placebo
Comparison 7. Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change (112 days or cycle 4) Show forest plot

1

191

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.79, 0.55]

Figuras y tablas -
Comparison 7. Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen
Comparison 8. Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean body mass percentage change (cycle 6) Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐1.54, 1.74]

Figuras y tablas -
Comparison 8. Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg
Comparison 9. Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

801

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.84 [0.58, 1.22]

2 Lost >2 kg (cycle 6) Show forest plot

1

801

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.65 [1.13, 2.41]

3 Gained >2 kg (cycle 12) Show forest plot

1

1476

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.85, 1.49]

4 Lost >2 kg (cycle 12) Show forest plot

1

1476

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.68, 1.33]

Figuras y tablas -
Comparison 9. Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg
Comparison 10. Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean body mass percentage change (cycle 6) Show forest plot

1

42

Mean Difference (IV, Fixed, 95% CI)

0.60 [‐1.45, 2.65]

Figuras y tablas -
Comparison 10. Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg
Comparison 11. Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

469

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.29 [1.84, 5.88]

Figuras y tablas -
Comparison 11. Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg
Comparison 12. Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 7) Show forest plot

1

890

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.20 [0.86, 1.68]

Figuras y tablas -
Comparison 12. Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen
Comparison 13. Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

196

Mean Difference (IV, Fixed, 95% CI)

0.57 [‐0.42, 1.56]

Figuras y tablas -
Comparison 13. Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen
Comparison 14. Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.20 [0.32, 4.51]

2 Lost >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.10 [0.14, 358.08]

Figuras y tablas -
Comparison 14. Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg
Comparison 15. Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.24, 3.76]

2 Lost >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.40 [0.45, 121.93]

Figuras y tablas -
Comparison 15. Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg
Comparison 16. Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 3) Show forest plot

1

48

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.77 [0.18, 3.21]

2 Lost >5% baseline weight (cycle 3) Show forest plot

1

48

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

Figuras y tablas -
Comparison 16. Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg
Comparison 17. Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

21

Mean Difference (IV, Fixed, 95% CI)

0.22 [‐1.30, 1.74]

Figuras y tablas -
Comparison 17. Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg
Comparison 18. Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

16

Mean Difference (IV, Fixed, 95% CI)

1.14 [‐0.54, 2.82]

Figuras y tablas -
Comparison 18. Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg
Comparison 19. Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 3) Show forest plot

2

112

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.82]

2 Lost >2 kg (cycle 3) Show forest plot

1

66

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.99 [0.20, 19.82]

Figuras y tablas -
Comparison 19. Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg
Comparison 20. Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.50 [0.05, 5.06]

2 Lost >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.92 [1.79, 55.04]

Figuras y tablas -
Comparison 20. Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 21. Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.13 [0.01, 2.13]

2 Lost >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

Figuras y tablas -
Comparison 21. Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 22. Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 13) Show forest plot

1

56

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.86 [0.29, 2.56]

2 Lost >2 kg (cycle 13) Show forest plot

1

56

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.38 [0.29, 6.62]

Figuras y tablas -
Comparison 22. Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 23. Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 7) Show forest plot

1

441

Mean Difference (IV, Fixed, 95% CI)

‐0.67 [‐1.16, ‐0.18]

Figuras y tablas -
Comparison 23. Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg
Comparison 24. Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.13 [0.01, 2.13]

2 Lost >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

Figuras y tablas -
Comparison 24. Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 25. Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐1.43, 2.03]

Figuras y tablas -
Comparison 25. Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg
Comparison 26. Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

39

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.05 [0.06, 17.51]

2 Lost >2 kg (cycle 6) Show forest plot

1

39

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.79 [0.15, 393.02]

3 Gained >2 kg (cycle 12) Show forest plot

1

452

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.06 [0.63, 1.81]

4 Lost >2 kg (cycle 12) Show forest plot

1

452

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.63, 2.03]

5 Gained >2 kg (cycle 13) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.71 [0.14, 3.57]

6 Lost >2 kg (cycle 13) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.82]

Figuras y tablas -
Comparison 26. Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg
Comparison 27. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean body mass percentage change (cycle 6) Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

0.7 [‐1.32, 2.72]

2 Mean weight change in kg (cycle 6) Show forest plot

1

805

Mean Difference (IV, Fixed, 95% CI)

0.20 [0.00, 0.40]

3 Mean weight change in kg (cycle 12) Show forest plot

2

462

Mean Difference (IV, Fixed, 95% CI)

0.01 [‐0.50, 0.51]

Figuras y tablas -
Comparison 27. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg
Comparison 28. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

3

1524

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.18 [0.87, 1.60]

2 Lost >2 kg ( cycle 6) Show forest plot

2

1172

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.34 [0.90, 2.00]

3 Mean body mass percentage change (cycle 6) Show forest plot

1

46

Mean Difference (IV, Fixed, 95% CI)

0.8 [‐1.18, 2.78]

Figuras y tablas -
Comparison 28. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 29. Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

357

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.54 [0.92, 2.60]

2 Mean body mass percentage change (cycle 6) Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

1.3 [‐1.03, 3.63]

Figuras y tablas -
Comparison 29. Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg
Comparison 30. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

30

Mean Difference (IV, Fixed, 95% CI)

1.25 [‐1.22, 3.72]

Figuras y tablas -
Comparison 30. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 31. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

47

Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐1.09, 0.59]

Figuras y tablas -
Comparison 31. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg
Comparison 32. Prolonged gestodene and EE regimen versus standard gestodene and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

58

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐1.23, 1.23]

Figuras y tablas -
Comparison 32. Prolonged gestodene and EE regimen versus standard gestodene and EE regimen
Comparison 33. Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

418

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.26 [0.74, 2.15]

2 Lost >2 kg (cycle 6) Show forest plot

1

418

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.70, 2.44]

Figuras y tablas -
Comparison 33. Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 34. Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.5 kg (cycle 24) Show forest plot

1

17

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.66 [0.77, 97.74]

2 Lost >2.5 kg (cycle 24) Show forest plot

1

17

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.88 [0.17, 21.18]

Figuras y tablas -
Comparison 34. Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 35. Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

369

Mean Difference (IV, Fixed, 95% CI)

0.7 [0.14, 1.26]

Figuras y tablas -
Comparison 35. Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg
Comparison 36. Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.7 kg (cycle 6) Show forest plot

1

109

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.92 [0.74, 4.96]

Figuras y tablas -
Comparison 36. Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 37. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

314

Mean Difference (IV, Fixed, 95% CI)

‐0.02 [‐0.06, 0.03]

Figuras y tablas -
Comparison 37. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 38. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean BMI change (cycle 6) Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

0.35 [‐0.13, 0.83]

2 Mean weight change in kg (cycle 6) Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

1.30 [‐0.32, 2.92]

Figuras y tablas -
Comparison 38. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg
Comparison 39. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

33

Mean Difference (IV, Fixed, 95% CI)

0.78 [‐0.28, 1.84]

Figuras y tablas -
Comparison 39. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg
Comparison 40. Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

21

Mean Difference (IV, Fixed, 95% CI)

0.92 [‐1.25, 3.09]

Figuras y tablas -
Comparison 40. Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg
Comparison 41. Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

0.09 [‐1.15, 1.33]

Figuras y tablas -
Comparison 41. Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen
Comparison 42. Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.5 kg (cycle 12) Show forest plot

1

228

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.75 [0.98, 3.11]

2 Lost >2.5 kg (cycle 12) Show forest plot

1

228

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.66 [0.25, 1.77]

Figuras y tablas -
Comparison 42. Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg
Comparison 43. Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

144

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐0.70, 0.90]

Figuras y tablas -
Comparison 43. Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg
Comparison 44. Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

349

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.15 [0.65, 2.06]

2 Mean body mass percentage change (cycle 6) Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

‐0.5 [‐2.51, 1.51]

Figuras y tablas -
Comparison 44. Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg
Comparison 45. Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.09 [0.60, 1.99]

2 Lost >2 kg (cycle 6) Show forest plot

1

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.69 [0.89, 3.20]

Figuras y tablas -
Comparison 45. Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 46. Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

5328

Mean Difference (IV, Fixed, 95% CI)

0.26 [0.12, 0.40]

Figuras y tablas -
Comparison 46. Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg
Comparison 47. Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Weight gain >=5% (cycle 6) Show forest plot

1

2157

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.15 [0.91, 1.45]

2 Weight gain >=5% (cycle 13) Show forest plot

1

453

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.09 [0.69, 1.74]

3 Weight loss >=5% (cycle 6) Show forest plot

1

2157

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.72, 1.37]

4 Weight loss >=5% (cycle 13) Show forest plot

1

453

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.32 [0.74, 2.34]

Figuras y tablas -
Comparison 47. Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg
Comparison 48. Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

1.8 [‐0.73, 4.33]

Figuras y tablas -
Comparison 48. Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen
Comparison 49. Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

3029

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.04, 0.30]

Figuras y tablas -
Comparison 49. Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg
Comparison 50. Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gain >2 kg (cycle 4) Show forest plot

1

51

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.69 [0.13, 3.58]

2 Lost >2 kg (cycle 4) Show forest plot

1

51

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.69 [0.35, 8.07]

Figuras y tablas -
Comparison 50. Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg
Comparison 51. Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gain >=7% body weight (cycle 13) Show forest plot

1

1030

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.84 [0.55, 1.28]

2 Lost >=7% body weight (cycle 13) Show forest plot

1

1030

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.39 [0.83, 2.32]

Figuras y tablas -
Comparison 51. Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 52. Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 13 or last assessment) Show forest plot

1

937

Mean Difference (IV, Fixed, 95% CI)

0.4 [0.03, 0.77]

Figuras y tablas -
Comparison 52. Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg